Figure 13. PET images comparing temporal lobe uptake of [18F]FDDNP (see text), an amyloid-binding radiotracer, and FDG, a marker of glucose metabolism, in a patient with AD (left) and a control subject (right). Note increased uptake and retention of [18F]FDDNP (arrowheads) in temporal lobes of the patient with AD, compared with those in control subject. The patient with AD still demonstrates typical findings of decreased temporal (arrows) and parietal (not shown) FDG uptake.